Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Frances Chow; François Lamoureux; Gatien Moriceau

doi:10.3389/fimmu.2024.1487952

Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Front Immunol. 2024 Sep 26:15:1487952. doi: 10.3389/fimmu.2024.1487952. eCollection 2024.

Authors

Frances Chow¹, François Lamoureux², Gatien Moriceau³

Affiliations

¹ Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
² CRCI2NA/INSERM UMR 1307/CNRS UMR 6075/Nantes Université, Nantes, France.
³ Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.

No abstract available

Keywords: antibody drug conjugate (ADC); cancer; combination therapy; drug resistance; immunotherapy; next generation therapeutics; targeted therapy.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Animals
Antineoplastic Agents / therapeutic use
Humans
Molecular Targeted Therapy
Mutation*
Neoplasms* / genetics
Neoplasms* / therapy

Substances

Antineoplastic Agents